Welcome to our dedicated page for Camp4 Therapeutics SEC filings (Ticker: CAMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CAMP4 Therapeutics Corporation filings document a clinical-stage biopharmaceutical issuer focused on regulatory RNA-targeting antisense oligonucleotide therapeutics. Its 8-K reports furnish operating results, corporate presentations and program updates for CMP-002 and the company's broader regRNA mapping and ASO discovery work, while material-agreement disclosures describe research, collaboration and license arrangements tied to neurodegenerative and kidney disease targets.
Proxy materials cover board elections, auditor ratification and equity incentive plan matters. Other filings address director appointments, compensatory arrangements, stock-based compensation, capital-structure disclosures, shareholder voting matters and the company’s emerging growth company status.
CAMP4 Therapeutics Corporation has registered for resale up to 10,795,804 shares of common stock and 21,925,368 shares issuable upon exercise of 2026 pre-funded warrants, all held by existing investors from a prior private placement. The company is not selling any shares and will not receive proceeds from resale, but may receive cash only if the pre-funded warrants are exercised.
CAMP4 is a clinical-stage biopharmaceutical company developing RNA-targeting therapeutics, led by CMP-002 for SYNGAP1-related disorder, with Phase 1/2 clinical trials cleared in Australia. The second closing of its private placement on August 3, 2026 raised gross proceeds of $50.1 million via common stock and 2026 pre-funded warrants. The registered shares represent about 38.6% of outstanding common stock as of August 3, 2026, which the company notes could pressure the share price if sold in volume. Any cash proceeds from warrant exercises are intended to fund CMP-002 development and general corporate purposes.
Trails Edge Capital Partners, LP, Trails Edge Biotechnology Master Fund, LP and Ortav Yehudai report beneficial ownership of Camp4 Therapeutics Corp common stock. As of August 3, 2026, they may be deemed to beneficially own 3,790,636 shares of Camp4 common stock, representing 6% of the outstanding shares. All reported shares are held directly by Trails Edge Biotechnology, with Trails Edge Capital as investment manager and Mr. Yehudai exercising voting and investment discretion. Camp4 had 62,753,200 shares outstanding as of the same date, as referenced from its Form S-3.
CAMP4 Therapeutics Corporation is registering for resale up to 10,795,804 shares of common stock and 21,925,368 shares issuable upon exercise of 2026 pre-funded warrants held by existing investors. This is a secondary offering by selling stockholders; CAMP4 is not selling new shares.
The resale shares, assuming full warrant exercise, represented about 38.6% of common stock outstanding as of August 3, 2026, creating potential share overhang. CAMP4 will receive cash only if the 2026 pre-funded warrants are exercised, at an exercise price of $0.0001 per share, and intends to use any such proceeds to fund development of its lead ASO candidate CMP-002 for SYNGAP1-related disorder and for working capital.
The registration fulfills rights granted in a private placement completed in two closings that raised $46.7 million net initially and $50.1 million gross at the second closing, with shares and pre-funded warrants sold at prices around $1.53–$1.65 per share.
CAMP4 Therapeutics Corporation’s major venture backer group led by 5AM funds updates its reported holdings after a second closing of a financing. As of that closing, 5AM-affiliated entities collectively report beneficial ownership of up to 6,313,434 shares of common stock for Andrew J. Schwab, or about 9.99%, and 6,304,434 shares for Dr. Kush Parmar, or about 9.98%, based on 62,753,200 shares outstanding.
At the second closing on August 3, 2026, the company issued 10,756,498 shares at $1.53 per share and 21,925,368 Pre-Funded Warrants at $1.5299 each, plus 39,306 additional shares to management at $1.65 per share. Ventures VII purchased 3,179,558 Pre-Funded Warrants for $4.9 million, funded by its partners. These Pre-Funded Warrants are immediately exercisable at $0.0001 per share, do not expire, and are subject to a 9.99% Beneficial Ownership Blocker limiting post-exercise ownership.
Camp4 Therapeutics Corp reported that major shareholder 5AM Ventures VII, L.P. purchased 3,179,558 pre-funded warrants at $1.5299 per warrant. Each warrant is exercisable immediately for one share of common stock at $0.0001 per share, has no expiration, and is subject to a 9.99% beneficial ownership cap. The warrants are held indirectly through 5AM Ventures VII, with related entities and individuals disclaiming beneficial ownership beyond their pecuniary interests.
Camp4 Therapeutics Corp director Andrew J. Schwab reported that affiliated fund 5AM Ventures VII, L.P. received 3,179,558 Pre-Funded Warrants to buy an equal number of common shares at an exercise price of 0.0001 per share. The warrants are immediately exercisable, have no expiration, and include a 9.99% beneficial ownership cap for Ventures VII and its Attribution Parties.
Camp4 Therapeutics Corp director Richard A. Young purchased 16,378 shares of common stock on August 3, 2026 at $1.65 per share. The shares were acquired in the second closing of a private placement under a Securities Purchase Agreement, increasing his direct holdings to 186,388 shares.
Camp4 Therapeutics Corp Chief Medical Officer Yuri Maricich purchased 6,551 shares of common stock on August 3, 2026 in the second closing of a private placement at $1.65 per share under a Securities Purchase Agreement. After this transaction, he directly holds 12,611 common shares.
Camp4 Therapeutics Corp disclosed that its Chief Financial Officer, Kelly Gold, purchased 6,551 shares of common stock on August 3, 2026 at $1.65 per share. The shares were acquired in the second closing of a private placement under a Securities Purchase Agreement with the issuer and various investors. Following this transaction, Gold directly owns 74,428 shares of Camp4 Therapeutics common stock. The Rule 10b5-1 checkbox was not marked for this transaction.